Full-gland TULSA-PRO seems to treat PSA without eradicating the cancer. In about a third of favorable-risk patients, the cancer remained viable in spite of the thermal ablation. We see that compared to whole-gland SBRT, it is less curative, Severe (requiring intervention) acute urinary toxicity is higher with TULSA-PRO, although late-term Grade 2 urinary toxicity is lower (not severe for either therapy). Rectal toxicity is not an issue for either therapy. Potency preservation is good and about equal for both.
It is hard to see why anyone would choose TULSA-PRO over SBRT. While focal ablation may incur less toxicity, the local recurrence rate will be higher. This trial suggests that TULSA-PRO is inferior, although only a direct randomized comparison could prove that.
Thank you for your contribution. I have to admit this is disappointing news.
I was hopeful that Tulsa could be used as a treatment that could preserve QOL, kill all of the PC and avoid the harmful effects of radiation.
I know this question is off topic but when I was getting treated at Mayo with Proton Therapy (pencil beam) I asked the resident Oncologist what percentage of patients get a secondary cancer from radiation treatment to the prostrate.
He told me about 1 and 20,000. I was wondering if there was any research papers that talk about that.
It seems to be very small, and is incredibly difficult to know. Here is what I've seen:
prostatecancer.news/2016/08...
Thank you.